MCID: KRT001
MIFTS: 62

Keratoconjunctivitis Sicca

Categories: Rare diseases, Eye diseases

Aliases & Classifications for Keratoconjunctivitis Sicca

MalaCards integrated aliases for Keratoconjunctivitis Sicca:

Name: Keratoconjunctivitis Sicca 12 76 53 29 55 44 15 73
Keratitis Sicca 53 73
Xerophthalmia 53 73
Dry Eye Syndromes 73
Dry Eye Syndrome 53
Kcs 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

Disease Ontology 12 DOID:12895
MeSH 44 D007638

Summaries for Keratoconjunctivitis Sicca

MalaCards based summary : Keratoconjunctivitis Sicca, also known as keratitis sicca, is related to keratoconjunctivitis and dry eye syndrome, and has symptoms including dryness of eye, eye manifestations and dacryops. An important gene associated with Keratoconjunctivitis Sicca is LTF (Lactotransferrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Miconazole and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and testes, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 76 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Keratoconjunctivitis Sicca

Diseases related to Keratoconjunctivitis Sicca via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 327)
# Related Disease Score Top Affiliating Genes
1 keratoconjunctivitis 31.4 CD79A IL4 NGF TLR9 TNF
2 dry eye syndrome 31.4 IL6 LTF NGF TNF
3 corneal disease 30.6 IL1A NGF TLR9
4 chronic graft versus host disease 29.8 ALB CD79A IL10 IL1A
5 uveitis 29.4 IL10 IL1A IL4 TNF
6 juvenile rheumatoid arthritis 29.2 IL1B IL6 TNF
7 arthritis 28.2 IL10 IL1A IL1B IL6 TNF
8 graft-versus-host disease 28.0 IL10 IL1A IL1B IL6 TNF
9 chlamydia 27.8 CD79A IL10 IL1B IL6 TNF
10 peritonitis 27.6 ALB IL10 IL1B IL6 TNF
11 pneumonia 27.6 IL10 IL1B IL6 TLR9 TNF
12 rheumatoid arthritis 27.4 CD79A IL10 IL1A IL1B IL4 IL6
13 colitis 27.2 IL10 IL1B IL4 IL6 TLR9 TNF
14 otitis media 27.2 ALB CD79A IL10 IL1B IL6 TNF
15 diabetes mellitus 27.1 ALB IL1A IL1B IL6 TNF
16 autoimmune disease 26.5 CD79A IL10 IL1B IL4 IL6 TLR9
17 xerophthalmia 12.6
18 sjogren syndrome 12.1
19 myelopathy, htlv-1-associated 11.2
20 aplasia of lacrimal and salivary glands 11.2
21 tropical spastic paraparesis 11.2
22 retrovirus-associated myelopathy 11.2
23 cork-handlers' disease 10.9 ALB CD79A
24 ostertagiasis 10.9 ALB CD79A
25 dermatitis, atopic, 3 10.9 ALB CD79A
26 neuroschistosomiasis 10.8 CD79A NGF
27 congenital hypogammaglobulinemia 10.8 CD79A IL1A IL4
28 root caries 10.8 ALB CD79A LTF
29 parotitis 10.8 ALB CD79A LTF
30 hyperglobulinemic purpura 10.7 CD79A HSPG2
31 ocular cicatricial pemphigoid 10.6 CD79A IL4 NGF
32 autoimmune disease of urogenital tract 10.5 ALB CD79A TLR9
33 dysentery 10.5 ALB CD79A IL1A LTF
34 pneumocystosis 10.5 ALB CD79A TNF
35 chronic follicular conjunctivitis 10.5 CD79A IL1A IL1B
36 guillain-barre syndrome 10.4 ALB CD79A TNF
37 bronchitis 10.4 ALB CD79A TNF
38 membranous nephropathy 10.3 ALB CD79A TNF
39 hypersensitivity reaction type iv disease 10.3 CD79A TLR9 TNF
40 skin conditions 10.3 IL1A TNF
41 gastroesophageal junction adenocarcinoma 10.3 ERBB2 IL1B
42 systemic onset juvenile idiopathic arthritis 10.3 IL1B TNF
43 transient arthritis 10.3 ALB IL1A IL6
44 scorpion envenomation 10.3 IL6 TNF
45 staphylococcal toxic shock syndrome 10.3 IL1B TNF
46 proliferative glomerulonephritis 10.3 CD79A IL4 IL6
47 hypersensitivity reaction type iii disease 10.3 ALB CD79A IL6
48 lichen planus 10.2 IL4 TLR9 TNF
49 autoimmune myocarditis 10.2 IL1B TNF
50 haemophilus influenzae 10.2 IL1B LTF TNF

Graphical network of the top 20 diseases related to Keratoconjunctivitis Sicca:



Diseases related to Keratoconjunctivitis Sicca

Symptoms & Phenotypes for Keratoconjunctivitis Sicca

UMLS symptoms related to Keratoconjunctivitis Sicca:


dryness of eye, eye manifestations, dacryops

MGI Mouse Phenotypes related to Keratoconjunctivitis Sicca:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 IL6 IL1A IL1B IL4 IL10 TLR9
2 immune system MP:0005387 10.3 IL6 IL1A IL1B IL4 IL10 NRTN
3 cellular MP:0005384 10.28 IL6 IL4 IL10 TLR9 LTF TNF
4 hematopoietic system MP:0005397 10.27 IL6 IL1A IL1B IL4 IL10 VSIG4
5 cardiovascular system MP:0005385 10.25 IL1A IL6 IL1B IL10 VSIG4 TNF
6 digestive/alimentary MP:0005381 10.22 IL6 IL4 IL10 NRTN TLR9 TNF
7 mortality/aging MP:0010768 10.15 IL10 IL6 IL1B IL4 VSIG4 TLR9
8 integument MP:0010771 10.13 IL6 IL1A IL1B IL4 IL10 TNF
9 endocrine/exocrine gland MP:0005379 10.11 IL4 IL10 IL6 NRTN TNF ERBB2
10 liver/biliary system MP:0005370 10.01 IL6 IL4 IL10 TNF LTF ALB
11 muscle MP:0005369 9.97 IL6 IL10 NRTN TNF NGF ALB
12 neoplasm MP:0002006 9.96 IL6 IL1A IL1B LTF IL10 TNF
13 nervous system MP:0003631 9.9 IL6 IL1B IL4 IL10 NRTN TNF
14 normal MP:0002873 9.56 IL10 IL4 NGF LTF ERBB2 ALB
15 respiratory system MP:0005388 9.17 IL10 IL6 IL4 TNF HSPG2 ERBB2

Drugs & Therapeutics for Keratoconjunctivitis Sicca

Drugs for Keratoconjunctivitis Sicca (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 340)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 9004-61-9 53477741
3
Povidone Approved Phase 4,Not Applicable 9003-39-8
4
Dipivefrin Approved Phase 4,Phase 3,Not Applicable 52365-63-6 3105
5
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 299-42-3 9294
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90-82-4 7028
7
Travoprost Approved Phase 4 157283-68-6 5282226
8
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
9
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
10
Prednisone Approved, Vet_approved Phase 4,Phase 1 53-03-2 5865
11
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 23994
12
Loteprednol Approved Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
13
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
14
Menthol Approved Phase 4,Phase 2,Not Applicable 2216-51-5 16666
15
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
16
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
17
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 104987-11-3 445643 439492
18
Azithromycin Approved Phase 4 83905-01-5 55185 447043
19
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
20
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 83-43-2 6741
21
Ofloxacin Approved Phase 4 82419-36-1 4583
22
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 50-24-8 5755
23
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
24
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
25
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
26
Latanoprost Approved, Investigational Phase 4,Phase 3,Not Applicable 130209-82-4 5282380 5311221
27
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
28
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
29
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
30
Sulfacetamide Approved Phase 4 144-80-9 5320
31
Tobramycin Approved, Investigational Phase 4,Phase 1,Not Applicable 32986-56-4 5496 36294
32
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
33
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
34
Doxazosin Approved Phase 4 74191-85-8 3157
35
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
36
Oxybutynin Approved, Investigational Phase 4,Not Applicable 5633-20-5 4634
37
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
38
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
39
Sorbitol Approved Phase 4,Not Applicable 50-70-4 5780
40
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
41
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
42
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
43
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Not Applicable 1406-66-2 14986
44
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
45
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 1406-16-2
46
Vitamin D3 Approved, Nutraceutical Phase 4,Not Applicable 67-97-0 6221 5280795
47
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-02-9 14985
48
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
49
Castor oil Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Not Applicable 8001-79-4
50
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795

Interventional clinical trials:

(show top 50) (show all 798)
# Name Status NCT ID Phase Drugs
1 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
4 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
5 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
6 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
7 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
8 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Unknown status NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
9 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
10 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
11 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
12 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
13 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
14 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
15 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
16 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
17 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
18 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
19 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
20 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
21 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
22 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
23 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
24 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
25 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
26 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
27 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
28 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
29 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
30 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
31 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
32 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
33 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
34 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
35 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
36 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
37 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
38 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
39 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
40 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
41 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
42 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
43 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
44 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
45 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
46 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
47 The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED Completed NCT02120079 Phase 4 Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
48 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
49 Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye Subjects Completed NCT01086774 Phase 4
50 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo

Search NIH Clinical Center for Keratoconjunctivitis Sicca

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: keratoconjunctivitis sicca

Genetic Tests for Keratoconjunctivitis Sicca

Genetic tests related to Keratoconjunctivitis Sicca:

# Genetic test Affiliating Genes
1 Keratoconjunctivitis Sicca 29

Anatomical Context for Keratoconjunctivitis Sicca

MalaCards organs/tissues related to Keratoconjunctivitis Sicca:

41
Eye, Salivary Gland, Testes, Thyroid, Bone, B Cells, Bone Marrow

Publications for Keratoconjunctivitis Sicca

Articles related to Keratoconjunctivitis Sicca:

(show top 50) (show all 358)
# Title Authors Year
1
Assessment of corneal and conjunctival metaplasia by impression cytology during the treatment of canine keratoconjunctivitis sicca. ( 29958527 )
2018
2
Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca. ( 29445621 )
2018
3
Efficacy of HL036 versus Cyclosporine A in the Treatment of Naturally Occurring Canine Keratoconjunctivitis Sicca. ( 29634381 )
2018
4
Autonomic reinnervation and functional regeneration in autologous transplanted submandibular glands in patients with severe keratoconjunctivitis sicca. ( 29695713 )
2018
5
Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast. ( 29958030 )
2018
6
Nuclear parameters and chromatin remodeling in epithelial cells and lymphocytes from the palpebral conjunctiva of dogs with keratoconjunctivitis sicca. ( 29493861 )
2018
7
Optimising tear replacement rheology in canine keratoconjunctivitis sicca. ( 29303147 )
2018
8
Clinical trials with multiple endpoints can establish a correlation, but not (yet) causality, between dietary supplementation with omega-3 fatty acids and keratoconjunctivitis sicca. ( 29781353 )
2018
9
Microvascular Submandibular Gland Transplantation for Severe Keratoconjunctivitis Sicca: A Single-Institution Experience of 56 Cases. ( 29864431 )
2018
10
Rheumatoid factor isotype and Ro epitope distribution in primary SjAPgren syndrome and rheumatoid arthritis with keratoconjunctivitis sicca. ( 29936570 )
2018
11
Use of clinical vignette questionnaires to investigate the variation in management of keratoconjunctivitis sicca and acute glaucoma in dogs. ( 29275324 )
2018
12
Canine oral mucosa evaluation as a potential autograft tissue for the treatment of unresponsive keratoconjunctivitis sicca. ( 28470741 )
2017
13
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
14
Comparison between fish and linseed oils administered orally for the treatment of experimentally induced keratoconjunctivitis sicca in rabbits. ( 29038781 )
2017
15
Tear ferning in normal dogs and dogs with keratoconjunctivitis sicca. ( 29038779 )
2017
16
Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. ( 28218751 )
2017
17
Carbachol improves the secretion of transplanted submandibular glands during the latent period after microvascular autologous transplantation for severe keratoconjunctivitis sicca. ( 27094607 )
2016
18
Allogeneic Mesenchymal Stem Cell Transplantation in Dogs With Keratoconjunctivitis Sicca. ( 28003932 )
2016
19
Episcleral cyclosporine A implants for the management of unilateral keratoconjunctivitis sicca in an 8-year-old mare. ( 26945681 )
2016
20
Assessment of tear film osmolarity using the TearLab(a8c) osmometer in normal dogs and dogs with keratoconjunctivitis sicca. ( 27761982 )
2016
21
Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. ( 27653428 )
2016
22
Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca. ( 27658509 )
2016
23
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27490054 )
2016
24
Increased Straylight in Patients With Keratoconjunctivitis Sicca. ( 27032024 )
2016
25
Outcomes of different concentrations of human amniotic fluid in a keratoconjunctivitis sicca-induced mouse model. ( 26767655 )
2016
26
Pimecrolimus micelle exhibits excellent therapeutic effect for Keratoconjunctivitis Sicca. ( 26731192 )
2016
27
Immediate Effect of 3% Diquafosol Ophthalmic Solution on Tear MUC5AC Concentration and Corneal Wetting Ability in Normal and Experimental Keratoconjunctivitis Sicca Rat Models. ( 27791390 )
2016
28
Keratoconjunctivitis sicca exacerbation in a dog treated with systemic atenolol. ( 27071733 )
2016
29
Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. ( 25747049 )
2015
30
Human albumin eye drops as a therapeutic option for the management of keratoconjunctivitis sicca secondary to chronic graft-versus-host disease after stem-cell allografting. ( 26628876 )
2015
31
Effect of once daily topical 0.3% naltrexone on tear parameters and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: a double-masked randomized placebo-controlled clinical trial. ( 25675975 )
2015
32
Salivary gland scintigraphy in patients suffering from severe keratoconjunctivitis sicca. Evaluation of the viability of submandibular glands before and after transfer into the temporal fossa. ( 26083667 )
2015
33
Microvascular autologous submandibular gland transplantation in severe cases of keratoconjunctivitis sicca. ( 25664315 )
2015
34
Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits. ( 26466228 )
2015
35
Use of adipose-derived mesenchymal stem cells in keratoconjunctivitis sicca in a canine model. ( 25802852 )
2015
36
Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca. ( 24395332 )
2014
37
Recurrent microbial keratitis in eyes with keratoconjunctivitis sicca with coexisting ocular surface pathology. ( 25378890 )
2014
38
Retrospective study of the prevalence of keratoconjunctivitis sicca in diabetic and nondiabetic dogs after phacoemulsification. ( 25429857 )
2014
39
Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in SjAPgren syndrome patients with or without punctal occlusions. ( 24977983 )
2014
40
The Role of Chlamydia Pneumoniae in the Etiology Keratoconjunctivitis Sicca (KCS). ( 25395268 )
2014
41
Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study. ( 24799029 )
2014
42
Uveodermatologic syndrome concurrent with keratoconjunctivitis sicca in a miniature poodle dog. ( 24891645 )
2014
43
A topical aqueous calcineurin inhibitor for the treatment of naturally occurring keratoconjunctivitis sicca in dogs. ( 22853450 )
2013
44
Infrared ocular thermography in dogs with and without keratoconjunctivitis sicca. ( 23905697 )
2013
45
Bilateral parotid duct transposition for keratoconjunctivitis sicca in a Connemara stallion. ( 23067239 )
2013
46
Long-term Supplementation With n-6 and n-3 PUFAs Improves Moderate-to-Severe Keratoconjunctivitis Sicca: A Randomized Double-Blind Clinical Trial. ( 23884332 )
2013
47
Use of linseed oil to treat experimentally induced keratoconjunctivitis sicca in rabbits. ( 23514268 )
2013
48
Microvascular autologous transplantation of partial submandibular gland for severe keratoconjunctivitis sicca. ( 23813419 )
2013
49
Punctal plugs versus artificial tears for treating primary SjAPgren's syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function. ( 23649850 )
2013
50
Corneal sequestrum in a dog with chronic unilateral keratoconjunctivitis sicca. ( 24299547 )
2013

Variations for Keratoconjunctivitis Sicca

Expression for Keratoconjunctivitis Sicca

Search GEO for disease gene expression data for Keratoconjunctivitis Sicca.

Pathways for Keratoconjunctivitis Sicca

Pathways related to Keratoconjunctivitis Sicca according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CD79A ERBB2 ERBB3 IL10 IL1A IL1B
2
Show member pathways
13.87 ERBB2 ERBB3 HSPG2 IL10 IL1A IL1B
3
Show member pathways
13.7 ERBB2 ERBB3 IL10 IL1A IL1B IL4
4
Show member pathways
13.53 ERBB2 ERBB3 IL10 IL1A IL1B IL4
5
Show member pathways
13.36 ERBB2 ERBB3 IL10 IL1A IL1B IL4
6
Show member pathways
13.34 ERBB2 ERBB3 IL10 IL1A IL1B IL4
7
Show member pathways
13.33 ERBB2 IL10 IL1A IL1B IL4 IL6
8
Show member pathways
13.01 ERBB2 ERBB3 IL4 IL6 NGF TNF
9
Show member pathways
12.92 IL10 IL1A IL1B IL4 IL6 TNF
10
Show member pathways
12.85 IL1A IL1B IL4 IL6 TLR9 TNF
11
Show member pathways
12.84 CD79A IL1A IL1B IL4 TLR9 TNF
12 12.82 ERBB2 ERBB3 IL1A IL1B NGF TNF
13
Show member pathways
12.75 IL1A IL1B IL6 NGF TLR9 TNF
14
Show member pathways
12.66 IL10 IL1A IL1B IL4 IL6 TNF
15
Show member pathways
12.63 ERBB2 IL10 IL1B IL6 TNF
16 12.6 CD79A IL10 IL1B IL4 TLR9 TNF
17
Show member pathways
12.55 IL1A IL1B NGF TLR9 TNF
18
Show member pathways
12.47 IL10 IL1A IL1B IL4 IL6 TNF
19
Show member pathways
12.45 ERBB2 ERBB3 IL1A IL1B
20
Show member pathways
12.43 IL10 IL1A IL1B IL4 IL6 TNF
21
Show member pathways
12.39 ALB IL1B IL4 IL6 TNF
22
Show member pathways
12.36 IL1B IL4 IL6 TNF
23 12.32 ERBB2 ERBB3 HSPG2 TNF
24
Show member pathways
12.32 IL10 IL1B IL6 TLR9 TNF
25
Show member pathways
12.32 IL10 IL1A IL1B IL4 TNF
26
Show member pathways
12.31 IL1A IL1B IL6 TNF
27
Show member pathways
12.3 IL1A IL6 TLR9 TNF
28
Show member pathways
12.26 IL1A IL1B IL6 TNF
29
Show member pathways
12.26 IL10 IL1B IL6 TLR9 TNF
30
Show member pathways
12.23 IL1B IL4 IL6 TLR9 TNF
31 12.19 IL10 IL1A IL1B IL6 TLR9 TNF
32
Show member pathways
12.13 IL10 IL1A IL1B IL4 IL6 NGF
33 12.09 IL10 IL1A IL1B IL6 NGF TNF
34
Show member pathways
12.07 ERBB2 ERBB3 IL1A IL1B TLR9
35 12.03 IL1A IL1B IL4 IL6 TNF